[8-K] Vera Therapeutics, Inc. Reports Material Event

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Vera Therapeutics (Nasdaq: VERA) filed an 8-K announcing a new Sales Agreement with TD Securities (USA) LLC (TD Cowen) dated 5 Aug 2025. The arrangement establishes an at-the-market (ATM) equity program permitting the company to issue and sell up to $200 million of Class A common stock under its effective shelf registration statement (Form S-3, File No. 333-282861).

TD Cowen will act as sales agent and/or principal, executing ordinary-course, block or negotiated transactions on Nasdaq or other trading venues. The company will pay a commission of up to 3.0 % of gross proceeds. Vera is under no obligation to sell shares, and either party may terminate the agreement by written notice. The filing simultaneously terminates the prior Sales Agreement dated 3 Jun 2022.

The program enhances funding flexibility without adding debt but could create dilution and share-price overhang if the full $200 million capacity is utilized.

Insights

TL;DR: New $200 m ATM improves liquidity but dilution risk; overall neutral until usage is disclosed.

The agreement offers Vera low-friction access to equity markets, supporting ongoing clinical development without taking on debt. At 3 % fees, the cost of capital is competitive with peers. However, management gave no timetable or cap on issuance cadence, so investors face uncertainty over near-term supply. Given the early-stage profile of the pipeline, immediate liquidity is strategically positive, but the potential 8-10 % share dilution (assuming execution near current market cap) tempers enthusiasm. Impact: neutral.

TL;DR: ATM adds fast capital but may pressure share price; mildly negative for existing holders.

ATM facilities are common, yet a $200 million limit is sizeable versus Vera鈥檚 average daily volume. Continuous discretionary sales can weigh on bid-ask spreads, especially in thin biotech names. The 3 % commission aligns with market norms, and termination flexibility protects both parties. Absent clear capital-allocation guidance, sell-side desks will price in supply risk, likely widening spreads and resetting technical resistance levels. Overall, I view the filing as modestly dilutive and therefore incrementally negative.

08/05/2025 - 04:56 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2025

Vera Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-40407

81-2744449

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

2000 Sierra Point Parkway, Suite 1200

Brisbane, California

94005

(Address of principal executive offices)

(Zip Code)

(650) 770-0077

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange

on which registered

Class A common stock, $0.001 par value per share

VERA

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01

Entry into a Material Definitive Agreement.

On August 5, 2025, Vera Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC (“TD Cowen”). Under the Sales Agreement, the Company may offer and sell, from time to time, through TD Cowen as its sales agent and/or principal, shares of its Class A common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering amount of up to $200 million (the “Shares”). The Sales Agreement replaces the prior Sales Agreement, dated June 3, 2022, by and between the Company and TD Cowen (as successor to Cowen and Company, LLC) (the “Prior Sales Agreement”), which was terminated as of August 5, 2025.

The Company is not obligated to sell any Shares under the Sales Agreement. Subject to the terms and conditions of the Sales Agreement, TD Cowen will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable laws and regulations, to sell Shares from time to time based upon the Company’s instructions, including any price, time or size limits or other customary parameters or conditions the Company may specify, subject to certain limitations. Under the Sales Agreement, TD Cowen may sell Shares in negotiated transactions, including block trades or block sales, or by any method that is deemed to be an “at-the-market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including without limitation sales made through the Nasdaq Global Market or on any other existing trading market for the Common Stock, or by any other method permitted by law. The Company will pay TD Cowen a commission of up to 3.0% of the gross sales proceeds of any Shares sold through TD Cowen under the Sales Agreement. The Company has also provided TD Cowen with customary indemnification and contribution rights. The Sales Agreement may be terminated by the Company or TD Cowen upon written notice to the other party in accordance with the terms of the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the termination of the Sales Agreement in accordance with its terms.

The issuance and sale, if any, of Shares under the Sales Agreement will be made pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-282861), filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 28, 2024, including the prospectus, dated October 28, 2024, and the Company’s prospectus supplement, dated August 5, 2025. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any Shares under the Sales Agreement nor shall there be any offer, solicitation or sale of such Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Cooley LLP, counsel to the Company, has issued a legal opinion relating to the validity of the Shares. A copy of such legal opinion, including the consent included therein, is filed as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The foregoing description of the material terms of the Sales Agreement is qualified in its entirety by reference to the full text of the Sales Agreement, which is attached as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 1.02

Termination of a Material Definitive Agreement.

The information set forth above in Item 1.01 with respect to the termination of the Prior Sales Agreement is hereby incorporated by reference into this Item 1.02.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.		Description

1.1		Sales Agreement, dated August 5, 2025, by and between Vera Therapeutics, Inc. and TD Securities (USA) LLC.

5.1		Legal Opinion of Cooley LLP.

23.1		Consent of Cooley LLP (included in Exhibit 5.1).

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	Vera Therapeutics, Inc.
Dated: August 5, 2025

	By:	/s/ Marshall Fordyce, M.D.
		Marshall Fordyce, M.D.
		Chief Executive Officer

Source:

AG真人官方